Raising Capital for Healthcare Companies: Which Investors Say Yes

Raising capital for healthcare companies works differently from raising for a typical software startup. The investors are more specialized, they look at fewer deals, and they want to see that your team understands how care is bought, paid for and delivered. Get that right and the pool of interested investors is real. Get it wrong and even a strong product gets passed over.

Health is one of the industries we work in at Investor Links. Here’s what the public data says about who is investing, what they check, and how to reach them.

How much money is going into healthcare companies right now?

For US digital health, quite a lot, but it’s concentrated. Rock Health reported that US digital health startups raised $3.7 billion across 114 deals in Q3 2026, bringing the year-to-date total to $11.1 billion across 358 deals. The year-to-date average deal size rose to $31.0 million, up from $29.5 million in 2025 and $20.6 million in 2024.

Big rounds take a large share. In its H1 2026 overview, Rock Health counted 20 rounds of $100 million or more, raised by 19 companies, and they made up 45% of all capital invested in the half. In Rock Health’s words, just over 8% of deals absorbed nearly half of the money. The median deal size was $14 million in H1, up from $12 million in 2025.

Two areas led. Mental health was the top-funded clinical area for the seventh year running, and weight management was second, per the same H1 report. Among mental health and weight management startups that raised, 64% sell directly to consumers, compared with 29% of all digital health companies.

A note on scope: Rock Health tracks US digital health only. It doesn’t cover biotech, drug development or most medical devices, and we didn’t find an equally reliable source for those, so we’re not quoting totals for them.

Which healthcare investors say yes?

Specialist healthcare VCs. These funds understand reimbursement, clinical evidence and long sales cycles, and they’re often the best lead for a healthcare round. In Rock Health’s Q3 update, Michael Greeley of Flare Capital describes today’s investor base as smaller and more experienced, with strategic investors filling in behind the generalists who left after COVID-19.

Strategic investors. These are the venture arms of health systems, insurers and large healthcare companies. They can bring a first customer or a distribution channel along with the money. They can also move slowly, and their interests won’t always match yours, so treat them as partners to vet, not just checks to collect.

Generalist VCs. Some still back healthtech, especially AI-heavy companies. Expect them to lean on outside experts during diligence.

Family offices. Interest is high, but few offices are set up to invest in startups. In J.P. Morgan’s 2026 Global Family Office Report, which surveyed 333 offices, 50% named healthcare innovation as an area they’re focused on or plan to prioritize, second only to AI at 65%. But 57% of those offices had no exposure to venture or growth equity at all. So look for offices with a family background in healthcare or a record of direct deals.

Angels. Physicians, former healthcare executives and founders who have sold a health company are often the first money in. We didn’t find a reliable public dataset on healthcare angels, so we’d rather not guess at numbers.

Why do healthcare investors look at fewer deals and dig deeper?

Because the risks are harder to judge from the outside. In the 2016 Gompers survey of 885 venture capitalists, a typical IT-focused VC firm considered 151 deals for every investment it made, while a healthcare VC firm considered only 78. The authors link this to the higher cost of evaluating healthcare deals and the smaller pool of founders with the right domain expertise.

The same study found healthcare VCs rank industry experience as by far the most important quality in a founding team, and that the time to close and the hours spent on diligence run longer for healthcare firms than for IT firms. They were also less flexible than IT investors on several deal terms, including board control.

Rock Health is hearing the same thing now. Its H1 report says earlier-stage investors describe domain expertise as more important than ever. Sean Doolan of Virtue told Rock Health: “Founder-market fit matters a lot right now.”

What this means for you: expect fewer, deeper conversations. Plan for a longer process than a software raise, and put your clinical or operating credibility on the first page.

What do healthcare investors ask for before a first call?

Here’s what we’d make sure is clear in your first message and deck:

• Who pays. Health system, insurer, employer, pharma or the patient. If reimbursement matters to your model, show where you stand on it.
• Evidence it works. Clinical outcomes, a published study, pilot results or measurable cost savings. Lisa Suennen of AHA Ventures told Rock Health that companies now compete on “deployable value”: how well they implement, integrate and execute.
• Regulatory path. Whether you need clearance or approval, and where you are in that process. Don’t guess at timelines; say what your regulatory advisor has told you.
• Who on the team has done this. A clinician, a former payer or health system executive, or a founder who has sold into hospitals before.
• Your round. Amount, stage, what’s committed and what the money gets you to.

For a deeper look at how investors weigh team, traction and fit, see our report on what investors look for.

What’s the right approach to raising capital for healthcare companies?

Pick fewer names and match them closely. A healthcare fund that only does medical devices won’t read a pitch for a care navigation app, however good it is. Look at each investor’s last few deals, their stage and their check size before you add them to your list.

Write to the person, not the firm. Name a portfolio company that relates to yours and say why. Lead with the clinical or business problem and your evidence, not the technology.

If you’re raising in the US from private investors, settle the securities side with your lawyer before outreach starts. Under the SEC’s Rule 506(b), you can’t use general solicitation or advertising. Under Rule 506(c), you can, but every buyer must be accredited and you must take reasonable steps to verify that.

How does Investor Links help healthcare founders?

We find the investors who fit your raise, write the messages, follow up and book the meetings. That means a checked list of healthcare-focused VCs, family offices, angels and others whose past deals and check sizes match yours, personalized outreach on LinkedIn and email through HeyReach and Instantly, and weekly numbers on opens, responses and meetings. We can also build or sharpen your pitch deck so it answers the questions above.

We don’t promise funding. We make sure the right healthcare investors see a clear, credible pitch. Book a free call to talk through your round.

Frequently asked questions